Apimeds Pharmaceuticals US Inc. (APUS)
APUS trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | APUS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Not reported by the screener |
| IPO year | 2025 |
| SEC CIK | 0001894525 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Recent IPO: no annual report filed yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued." | 10-Q 2026-08-14 |
| Cash and burn | $278K cash; operating cash flow -$3.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,509,118 (2026-08-12); 12,575,983 a year earlier. 1y figure adjusted for split (1-for-10 overall). | Cover page 2026-08-12 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2026-07-24 | Source 2026-07-24 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-22 |
| Auditor | Kreit & Chiu CPA LLP, New York, New York, United States | PCAOB Form AP 2026-05-08 |
| Late filings, 12 months | 2 NT notices | NT 10-Q 2026-05-15 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$20.2M | -$5.7M | $278K | $18.9M | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$35.1M | -$2.1M | $980K | $8.9M | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$1.2M | -$3.8M | $1.6M | $7.1M | Needs four quarters | 10-K 2026-05-04 |
| Q3 2025 2025-09-30 | Not filed | -$1.8M | -$1.7M | $7.0M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$2.7M | -$3.4M | $8.7M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$402K | -$20K | $250K | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$312K | -$100K | $3K | No debt tags | Needs four quarters | 10-K 2026-05-04 |
| Q3 2024 2024-09-30 | Not filed | -$333K | -$187K | $27K | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2025-05-09 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-05-04 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 131 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.6% |
| 1 month | -51.7% |
| 3 months | -52.6% |
| Year to date | -86.4% |
| 1 year | -92.0% |
| From 52-week high | -94.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RDHL | Redhill Biopharma Ltd. | $0.3605 | -3.87% | $3.2M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
| MDCX | Medicus Pharma Ltd. Common Stock | $1.69 | -13.33% | $3.2M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| SILO | Silo Pharma Inc. | $1.57 | -14.40% | $3.4M |
| ERNA | Ernexa Therapeutics Inc. | $1.69 | +0.60% | $2.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier